HIV/AIDs in the U.S.: Difference between revisions
Chavezerazoj (talk | contribs) No edit summary |
Chavezerazoj (talk | contribs) No edit summary |
||
Line 39: | Line 39: | ||
[3] [http://cid.oxfordjournals.org/content/60/suppl_3/S200.short= Jain S, Krakower DS, Mayer KH. "The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. 2015. Clinical Infectious Diseases. 60(S3):S2000-4.] | [3] [http://cid.oxfordjournals.org/content/60/suppl_3/S200.short= Jain S, Krakower DS, Mayer KH. "The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. 2015. Clinical Infectious Diseases. 60(S3):S2000-4.] | ||
[4] | [4] [http://jid.oxfordjournals.org/content/203/10/1484.short= Brown KC. et. al. (9 coauthors). "Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative Men. 2010. Journal of Infectious Diseases. 203:1484-90.] | ||
[5] | [5] |
Revision as of 13:55, 18 December 2015
An Introduction to HIV/AIDs
By Jorge Sebastian Chavez Erazo
A Basic explanation of Antiretroviral Treatments
Include some current research, with at least one figure showing data.
Pre-/Post-Exposure Prophylaxis
In recent years, pre-exposure and post exposure prophylactic treatments for populations at high risk for Human Immunodeficiency Virus (HIV) infection have become increasingly studied and emphasized as vital to the decreased transmission of HIV resulting in decreased rates of Advanced Immunodeficiency Syndrome (AIDS) development in differing world populations.
Pre-Exposure Prophylaxis
PrEP has given a specific population the opportunity to have a 90% reduction in the chance of contracting HIV with the use of the daily pill, Truvada (oral emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF)). The product is said to be available to any person regardless of their sexual and gender identity but in there lies the problem with PrEP, many people who are at high risk of contracting HIV are not receiving it.
.
Post-Exposure Prophylaxis
Include some current research, with at least one figure showing data.
Challenges to HIV/AIDs Prevention and Treatment
The product [PrEP] is said to be available to any person regardless of their sexual and gender identity but in there lies the problem with PrEP, many people who are at high risk of contracting HIV are not receiving it.
Conclusion
References
[5]
[6]
[7]
[8]
[9]
[10]
Authored for BIOL 291.00 Health Service and Biomedical Analysis, taught by Joan Slonczewski, 2016, Kenyon College.